{"id":1070,"date":"2025-02-20T15:09:00","date_gmt":"2025-02-20T20:09:00","guid":{"rendered":"https:\/\/usesparrow.com\/blog\/?p=1070"},"modified":"2025-08-21T04:41:35","modified_gmt":"2025-08-21T08:41:35","slug":"zicam-class-action-lawsuit-details","status":"publish","type":"post","link":"https:\/\/usesparrow.com\/blog\/zicam-class-action-lawsuit-details\/","title":{"rendered":"$6 Million Settlement: Zicam Class Action Lawsuit Details"},"content":{"rendered":"\n

Zicam, a well-known brand in the over-the-counter cold remedy industry, has agreed to a $6 million settlement<\/strong> to resolve allegations of false advertising. The Zicam class action lawsuit<\/strong> claimed that Zicam falsely marketed its products as being able to shorten the duration and severity of colds, misleading thousands of consumers across the United States.<\/p>\n\n\n\n

This article provides a comprehensive guide<\/strong> on what the settlement entails, who is eligible, the compensation amounts available, and how to file a claim. If you purchased a Zicam product before October 17, 2024<\/strong>, you might be entitled to reimbursement\u2014keep reading to learn how to secure your share of the settlement<\/strong>.<\/p>\n\n\n\n

Background: Why Was Zicam Sued?<\/strong><\/h2>\n\n\n\n

Zicam, owned by Church & Dwight Co., Inc.<\/strong> and manufactured by Matrixx Initiatives Inc.<\/strong>, is known for its zinc-based formulas that claim to provide fast relief from cold symptoms. The lawsuit alleges that despite these claims, Zicam products do not have sufficient scientific backing<\/strong> to prove they perform as advertised. Consumers who purchased these products based on these claims may have spent money on ineffective remedies.<\/p>\n\n\n\n

For years, Zicam has positioned itself as a trusted name in cold relief, offering homeopathic remedies such as nasal sprays, throat sprays, and lozenges. These products were widely advertised as scientifically backed solutions that could help users recover from colds faster. However, plaintiffs in the class action lawsuit argued that these claims were not supported by credible scientific evidence<\/strong>, ultimately leading to consumers spending money on products that did not deliver the promised results.<\/p>\n\n\n\n

\"zicam
Source: Bloomberg<\/figcaption><\/figure>\n\n\n\n

The class action lawsuit, Vance, et al. v. Church & Dwight Co. Inc., Case No. 24LA190<\/strong>, was filed in response to allegations that Zicam’s advertising was deceptive. Plaintiffs argued that the company’s marketing statements misled consumers into believing that Zicam products had clinically proven benefits in combating the common cold. Plaintiffs contended that:<\/p>\n\n\n\n